Debt-to-equity of Aptevo Therapeutics Inc. from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aptevo Therapeutics Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Aptevo Therapeutics Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 145%, a 13% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Aptevo Therapeutics Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 145% -22% -13% 30 Sep 2025
Q2 2025 285% +159% +127% 30 Jun 2025
Q1 2025 344% +244% +244% 31 Mar 2025
Q4 2024 221% +146% +197% 31 Dec 2024
Q3 2024 167% +93% +127% 30 Sep 2024
Q2 2024 125% +48% +62% 30 Jun 2024
Q1 2024 100% +25% +34% 31 Mar 2024
Q4 2023 74% -120% -62% 31 Dec 2023
Q3 2023 73% -331% -82% 30 Sep 2023
Q2 2023 77% -620% -89% 30 Jun 2023
Q1 2023 75% -1263% -94% 31 Mar 2023
Q4 2022 194% -498% -72% 31 Dec 2022
Q3 2022 405% -29% -6.8% 30 Sep 2022
Q2 2022 697% +262% +60% 30 Jun 2022
Q1 2022 1338% +968% +262% 31 Mar 2022
Q4 2021 693% +477% +220% 31 Dec 2021
Q3 2021 434% +178% +70% 30 Sep 2021
Q2 2021 435% +251% +136% 30 Jun 2021
Q1 2021 370% +188% +104% 31 Mar 2021
Q4 2020 216% +47% +28% 31 Dec 2020
Q3 2020 256% +117% +85% 30 Sep 2020
Q2 2020 185% +75% +68% 30 Jun 2020
Q1 2020 182% +94% +108% 31 Mar 2020
Q4 2019 169% +100% +144% 31 Dec 2019
Q3 2019 138% +84% +155% 30 Sep 2019
Q2 2019 110% +62% +131% 30 Jun 2019
Q1 2019 87% +38% +78% 31 Mar 2019
Q4 2018 69% +18% +34% 31 Dec 2018
Q3 2018 54% -6.4% -11% 30 Sep 2018
Q2 2018 48% -18% -28% 30 Jun 2018
Q1 2018 49% -6.3% -11% 31 Mar 2018
Q4 2017 52% +1.1% +2.2% 31 Dec 2017
Q3 2017 61% +16% +37% 30 Sep 2017
Q2 2017 66% 30 Jun 2017
Q1 2017 55% 31 Mar 2017
Q4 2016 51% 31 Dec 2016
Q3 2016 44% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.